期刊文献+

多西他赛单药与多西他赛联合化疗方案腹泻的临床观察

下载PDF
导出
摘要 目的观察多西他赛单药与多西他赛联合顺铂、多西他赛联合表柔比星化疗引起腹泻的临床观察。方法多西他赛联合顺铂方案:多西他赛75mg/m2第1天,顺铂75mg/m2第1天,每3周一次;多西他赛联合表柔比星方案:表柔比星75mg/m2第1天,多西他赛75mg/m2第1天,每3周一次;多西他赛单药方案:多西他赛35mg/m2第1、8、5天,每4周一次。结果多西他赛联合顺铂方案化疗患者16例,腹泻发生率37.5%(G3/4:6.25%);多西他赛联合表柔比星方案化疗患者13例,腹泻发生率38.4%(G3/4:7.6%);多西他赛单药方案化疗患者10例,腹泻发生率10.0%(G3/4:0)。结论多西他赛联合化疗方案较多西他赛单药化疗方案腹泻发生率明显升高,但无IV度腹泻发生,经治疗,腹泻均可治愈,无相关死亡发生。
作者 赵惠
出处 《中国实用医药》 2011年第2期138-139,共2页 China Practical Medicine
  • 相关文献

参考文献3

二级参考文献31

  • 1吴成利,秦叔逵.食管癌的化疗新进展[J].医师进修杂志(外科版),2005,28(4):6-8. 被引量:20
  • 2段家华,王志刚.国产多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中华肿瘤防治杂志,2006,13(17):1333-1335. 被引量:23
  • 3Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouraeil compared with eisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol, 2006,24(31 ) :4991 -4997. C.
  • 4rown J, O'Leary M. The taxanes: an update [ R ]. Lancet, 2000, 355(9210) :1176 - 1178.
  • 5Mai M, Sakata Y, Kanamaru R, et al. A late phase Ⅱ clinical study of RP56976(docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B ) [J]. Japanese Journal of Cancer and Chemotherapy, 1999, 26 (4) :487 -496.
  • 6Graziano F, Catalano V, Baldelli AM, et al. A phase Ⅱ study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer[J]. Ann Oncol,2000, 11:1263-1266.
  • 7Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase Ⅱ trial[ J]. Japanese Journal of Clinical Oncology, 2002,32:248 - 254.
  • 8Roth AD, Maibach R, Martinelli G, et al. Docetaxel(Taxoterecisplatin, TC) : an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research( SAKK), and the European Institute of Oncology(EIO) [ J]. Ann Oncol,2000, 11 (3) :301 - 306.
  • 9Ajani JA, Fodor M, Van Cutsem E et al. Multinational randomized phase Ⅱ trial of docetaxel (T) and cisplatin ( C ) with or without 5-fluorouracil(FU) in patients(pts) with advanced gastric or GE junction adenocarcinoma(AGC-AGEJC) [ J ]. Proc Am Soc Clin Oncol, 2000, 19:a247.
  • 10Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus cisplatin and fiuorouracil compared with cisplatin and fluorouracil from a phase Ⅲ trial for advanced gastric or gastroesophageal adenocarcinoma: the V325 study group [ J ]. J Clin Oncol,2007,25(22) : 3205 -3209.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部